Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obicetrapib, a selective cholesteryl ester transfer protein (CETP) inhibitor, reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), lipoprotein particles, and apolipoproteins, when added to high-intensity statin in patients with dyslipidemia. OBJECTIVE: To evaluate the safety and lipid-altering efficacy of obicetrapib plus ezetimibe combination therapy as an adjunct to high-intensity statin therapy. METHODS: This double-blind, randomized, phase 2 trial administered 10 mg obicetrapib plus 10 mg ezetimibe (n = 40), 10 mg obicetrapib (n = 39), or placebo (n = 40) for 12 weeks to patients with LDL-C >70 mg/dL and triglycerides (TG) <400 mg/dL, on stable high-intensity statin. Endpoints included concentrations of lipids, apolipoproteins, lipoprotein particles, and proprotein convertase subtilisin kexin type 9 (PCSK9), safety, and tolerability. RESULTS: ). LDL-C decreased from baseline to week 12 by 63.4%, 43.5%, and 6.35% in combination, monotherapy, and placebo groups, respectively (p<0.0001 vs. placebo). LDL-C levels of <100, <70, and <55 mg/dL were achieved by 100%, 93.5%, and 87.1%, respectively, of patients taking the combination. Both active treatments also significantly reduced concentrations of non-HDL-C, apolipoprotein B, and total and small LDL particles. Obicetrapib was well tolerated and no safety issues were identified. CONCLUSION: The combination of obicetrapib plus ezetimibe significantly lowered atherogenic lipid and lipoprotein parameters, and was safe and well tolerated when administered on top of high-intensity statin to patients with elevated LDL-C.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationEffects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationEffects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Martin, S. S., Blaha, M. J., Elshazly, M. B., Toth, P. P., Kwiterovich, P. O., Blumenthal, R. S., & Jones, S. R. (2013) · JAMA · doi:10.1001/jama.2013.280532 · Cited by 883
Ray, K. K., Molemans, B., Schoonen, W. M., Giovas, P., Bray, S., Kiru, G., Murphy, J., Banach, M., De Servi, S., Gaita, D., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa047 · Cited by 839
Evacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801
Self-citationVariation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604304 · Cited by 743
Wang, N., Woodward, M., Huffman, M. D., & Rodgers, A. (2022) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.121.008552 · Cited by 80
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib
Davidson, M., Liu, S. X., Barter, P., Brinton, E. A., Cannon, C. P., Gotto, A. M., Leary, E. T., Shah, S., Stepanavage, M., Mitchel, Y., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m032615 · Cited by 56
Self-citation
Cited by
Mach, F., Visseren, F. L. J., Cater, N. B., Salhi, N., Soronen, J., Ray, K. K., Delgado, V., Jukema, J. W., Laufs, U., Zamorano, J.-L., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.07.001 · Cited by 57
Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management
Agnello, F., Ingala, S., Laterra, G., Scalia, L., & Barbanti, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051251 · Cited by 39
“Recently, a phase II trial showed obicetrapib 10 mg, added to ezetimibe, and high-intensity statin decreased LDL-C by 55.6% [82].”
BackgroundInfluentialLipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis
Masson, W., Barbagelata, L., Lobo, M., Nogueira, J. P., & Handelsman, Y. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.12.016 · Cited by 23
Araújo, B., Arrighini, G. S., Queiroga, F., Mansouri, E. S., Rivera, A., Amador, W. F. O., Queiroz, I., Akabane, M. A. C. C., Consoli, L. N., Sobral, M. V. S., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101303 · Cited by 10
“Recent phase 2 and phase 3 trials demonstrated that combining obicetrapib with ezetimibe led to substantial additional LDL-C reductions, even in patients already on high-intensity statins, with no major safety signals [18,19].”
Metadata
- Authors
- Ballantyne, C. M., Ditmarsch, M., Kastelein, J. J., Nelson, A. J., Kling, D., Hsieh, A., Curcio, D. L., Maki, K. C., Davidson, M. H., & Nicholls, S. J.
- Venue
- Journal of Clinical Lipidology
- Publisher
- Elsevier BV
- Published
- 2023-07
- Volume
- 17
- Issue
- 4
- Pages
- 491-503
- ISSN
- 1876-4789 (ISSN-L)
- 1933-2874
- OpenAlex
- W4379259785
- Cited by
- 84
- References
- 12
- FWCI
- 20.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.